Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph
|Shares Outstanding||EPS||-1.02||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||5.98%||Sales Growth - Q/Q||-11.95%||P/E||-86.75|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-4.46%||ROE||-6.74%||ROI||-5.17%|
|Current Ratio||4.98||Quick Ratio||4.25||Long Term Debt/Equity||0.54||Debt Ratio||0.13|
|Gross Margin||82.59%||Operating Margin||-16.48%||Net Profit Margin||-20.35%||Dividend Payout Ratio|
|Cash From Financing Activities||914.79 M||Cash From Investing Activities||-750.87 M||Cash From Operating Activities||-137.81 M||Gross Profit||170.45 M|
|Net Profit||-67.5 M||Operating Profit||-66.02 M||Total Assets||3.66 B||Total Current Assets||1.52 B|
|Total Current Liabilities||305.51 M||Total Debt||655.49 M||Total Liabilities||1.23 B||Total Revenue||203.26 M|
|High 52 week||106.07||Low 52 week||76.01||Last close||76.99||Last change||0.13%|
|RSI||33.73||Average true range||2.22||Beta||1.08||Volume||685.95 K|
|Simple moving average 20 days||-3.78%||Simple moving average 50 days||-6.13%||Simple moving average 200 days||-13.32%|
|Performance Week||-1.09%||Performance Month||-6.93%||Performance Quart||-6.6%||Performance Half||-18.34%|
|Performance Year||-25.48%||Performance Year-to-date||-9.58%||Volatility daily||1.48%||Volatility weekly||3.31%|
|Volatility monthly||6.78%||Volatility yearly||23.47%||Relative Volume||211.9%||Average Volume||1.29 M|
|New High||New Low|
2019-09-15 15:28:47 | Stocks That Fell to 3-Year Lows in the Week of Sept. 13
2019-09-13 08:12:56 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Overpaying Its CEO?
2019-08-31 09:31:01 | BioMarin BMRN Down 7.3% Since Last Earnings Report: Can It Rebound?
2019-08-14 12:06:57 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Trading At A 31% Discount?
2019-08-08 16:29:20 | 6 Underperforming Stocks in Gurus' Portfolios
2019-08-08 10:33:02 | Sarepta SRPT Q2 Loss Widens Y/Y, Golodirsen Nears Approval
2019-08-06 10:45:00 | BioMarin's Roller Coaster Continues
2019-08-03 08:54:04 | Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT
2019-08-02 11:23:36 | Biomarin Pharmaceutical Inc BMRN Q2 2019 Earnings Call Transcript
2019-08-02 10:52:02 | BioMarin BMRN Shares Down on Q1 Earnings & Sales Miss
2019-08-02 09:15:00 | BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried
2019-08-01 18:05:10 | BioMarin Pharmaceutical BMRN Lags Q2 Earnings and Revenue Estimates
2019-08-01 16:05:00 | BioMarin Announces Second Quarter 2019 Financial Results
2019-07-31 09:15:01 | Rate Cut Wait Almost Over
2019-07-29 09:08:01 | What's in the Cards for Sarepta SRPT This Earnings Season?
2019-07-25 10:34:02 | BioMarin Pharmaceutical BMRN Reports Next Week: Wall Street Expects Earnings Growth
2019-07-16 08:03:12 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
2019-07-12 14:25:00 | Shake-Up in Big Weed
2019-07-10 05:57:58 | BioMarin Pharmaceutical Inc.'s NASDAQ:BMRN Shift From Loss To Profit
2019-07-10 05:43:59 | JP Morgan: 2 Gene Therapy Stocks to Buy Now
2019-07-09 10:40:02 | BioMarin BMRN to File for Hemophilia A Candidate in Q4
2019-07-09 08:02:20 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
2019-07-09 06:00:00 | 3 Top Biotech Stocks to Buy in July
2019-07-08 16:18:09 | Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals
2019-07-08 12:58:00 | Here's Why Sangamo Therapeutics Is Surging Today
2019-07-08 09:55:01 | Sarepta Stock Up Almost 40% This Year So Far: Here's Why
2019-07-03 12:03:54 | Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
2019-07-01 06:00:00 | Healthcare: Drugmakers and Providers Look Attractive
2019-06-26 08:31:00 | BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis ISTH 2019 Congress in Melbourne, Australia from July 6-10, 2019
2019-06-25 09:33:38 | Despite Recent Volatility, Biotech Stocks Look Poised to Pop
2019-06-24 11:04:03 | BioMarin Gets $15M From Pfizer on Talzenna's European Nod
2019-06-24 08:33:12 | Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
2019-06-17 13:52:12 | Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
2019-06-13 21:08:21 | Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
2019-06-12 07:30:00 | 9 major Bay Area tech employers pay a typical worker more than $200K per year
2019-06-11 10:24:02 | Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. BMRN
2019-06-10 09:03:39 | Should BioMarin Pharmaceutical NASDAQ:BMRN Be Disappointed With Their 32% Profit?
2019-06-10 08:04:04 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
2019-06-09 12:09:00 | 3 Top Growth Stocks to Buy in June
2019-06-06 10:33:02 | BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady